Navigation Links
Fluxion Biosciences Receives National Cancer Institute Grant for Development of ERASE-Seq Liquid Biopsy Technology
Date:2/27/2019

Fluxion Biosciences, a leading developer of precision solutions for life science research and diagnostics, today announced that it has received a National Cancer Institute grant for further development of its ERASE-Seq liquid biopsy technology. The Phase I grant will have a duration of 9 months, with clinical support from the lab of Dr. Omar Mian at the Cleveland Clinic.

Liquid biopsies offer the potential to improve treatment of cancer by providing affordable, non-invasive detection of actionable cancer mutations from a blood sample. However, the relative abundance of cancer DNA in blood is extremely low, and below the detection threshold for most assays. Analytical and clinical results have demonstrated that ERASE-Seq provides superior results compared to competitive approaches for sequencing circulating tumor DNA (ctDNA) isolated from blood.

The NCI project includes three main aims: 1) improvements to and validation of the ERASE-Seq bio-informatic algorithms to improve detection sensitivity and specificity, 2) automation of the ERASE-Seq data analysis pipeline, and 3) measuring sensitivity and accuracy of ERASE-Seq to competitive sequencing approaches and to an established “gold standard” technique using cancer patient blood samples.

“We are honored to receive this NCI grant and excited to develop the capabilities of our ERASE-Seq liquid biopsy”, stated Jeff Jensen, CEO. "Liquid biopsies offer tremendous promise, but advances are needed to improve the sensitivity and accuracy of these tests. ERASE-Seq offers the potential to deliver on the promise of cancer precision medicine: the right treatment for the right patient at the right time. We look forward to collaborating with Cleveland Clinic on this important program.”

Dr. Mian, Assistant Professor of Radiation Oncology at Cleveland Clinic, stated, “This collaboration demonstrates the innovation expected of a Small Business Innovative Research grant. It will provide the basis for the first ctDNA diagnostic for hepatocellular carcinoma, effectively changing the way the disease is diagnosed in the clinic. Additionally, if successful this will introduce researchers in other areas of oncology to a powerful method for ctDNA variant analysis.”

About Fluxion Biosciences

Fluxion’s liquid biopsy solutions are revolutionizing how cancer is detected and treated. Fluxion’s pioneering liquid biopsy technologies include the IsoFlux CTC Liquid Biopsy System, ERASE-Seq ultra-sensitive variant caller, and the Spotlight 59 NGS Oncology Panel for cancer mutation detection from cell-free circulating tumor DNA. Fluxion’s technologies are used globally by leading cancer centers developing new tests for early cancer detection and patient monitoring. For more information about Fluxion's liquid biopsy capabilities, visit liquidbiopsy.fluxionbio.com.

Read the full story at https://www.prweb.com/releases/fluxion_biosciences_receives_national_cancer_institute_grant_for_development_of_erase_seq_liquid_biopsy_technology/prweb16127477.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Inflection Biosciences licenses preclinical oncology programs from the CNIO
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Springer will publish lecture series with the Mathematical Biosciences Institute
4. Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
5. Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
6. The new Africa -- green shoots in biosciences
7. Pressure BioSciences Closes Additional $745,000 of $5 Million PIPE; Funding Received to Date Exceeds $4,000,000
8. ACEA Biosciences Introduces an Exploratory xCELLigence® RTCA S16 Instrument
9. ACEA Biosciences Releases New Version of NovoExpress® Flow Cytometry Software.
10. ACEA Biosciences Launches xCELLigence® RTCA Software Pro to Further Enhance Immuno-Oncology Experimental Design and Analysis
11. Tosoh Bioscience LLC invests in Semba Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2019)... CITY, and MARTINSRIED, Germany (PRWEB) , ... August ... ... high-throughput antibody screening and characterization, announced today that they have opened a Customer ... platform has fueled the need for the new office. , The Munich CEC ...
(Date:8/14/2019)... , ... August 13, 2019 , ... ... Team, Division of Molecular Pathology, Institute of Cancer Research (ICR) in a ... to learn about the process of biomarker and companion diagnostic development including machine ...
(Date:8/6/2019)... ... August 06, 2019 , ... ... manufacturing with clinical, regulatory and GMP manufacturing experience. In November it spun ... With extensive regulatory experience and one of the first cGMP cell ...
Breaking Biology News(10 mins):
(Date:6/26/2019)... ... ... Alice Branton today released research results from preclinical trials on the beneficial ... prove to be beneficial for treating Hypomagnesemia. , The preclinical trial shows:, ... , Over 142% increase in particle size , Over 3% ...
(Date:6/18/2019)... ... 18, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a human ... FDA for use of a person’s own adipose-derived stem cells to treat their osteoarthritis. ... knee. This IND is the first of several planned clinical trials which will ...
(Date:6/11/2019)... ... June 10, 2019 , ... ... distribution network with the appointment of Biofeedback Tech Ltd as its ... are an essential part of many therapeutic treatments and clinical assessment protocols to ...
(Date:6/11/2019)... , ... June 10, 2019 , ... ... IOPP will add 80 of its scientific journals to DeepDyve’s rental service for ... to DeepDyve’s continually expanding library of more than 20 million articles, sourced from ...
Breaking Biology Technology: